Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 125  
ORIGINAL ARTICLE
Year : 2016  |  Volume : 15  |  Issue : 1  |  Page : 24-29

Outcome of Radioiodine Therapy in a West African Population


1 Department of Nuclear Medicine, University College Hospital; Department of Radiotherapy, University of Ibadan, Ibadan, Oyo State, Nigeria
2 Department of Nuclear Medicine, National Centre for Radiotherapy and Nuclear Medicine, Korle Bu Hospital, Accra, Ghana
3 Department of Nuclear Medicine, University College Hospital, Chemical Pathology, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria

Correspondence Address:
Yetunde A Onimode
Department of Nuclear Medicine, University College Hospital, P.M.B. 5116, Mokola, Oyo State
Nigeria
Login to access the Email id


DOI: 10.4103/1450-1147.167585

PMID: 26912975

Rights and Permissions

Hyperthyroidism continues to be a pressing public health concern in West Africa. Its prevalence in Africa has been quoted as 1.2%-9.9%, with Graves' disease as its most common cause. Radioiodine-131 (RAI) therapy of hyperthyroidism recently commenced in two government hospitals in Ghana and Nigeria. This is a retrospective analysis of consecutive patients treated with RAI for primary hyperthyroidism at the National Centre for Radiotherapy and Nuclear Medicine (NCRNM) from 2008-2013, and in the University College Hospital (UCH) from 2006-2013. Cure was defined as euthyroidism or hypothyroidism occurring at 6 months post-RAI. Data were analysed using SPSS version 21 and Epi Info version, categorical data were evaluated with the Chi-square test and Fisher's exact test. 94 patients were studied, aged 20-74 years; 78 were females, and 16 were males. 38 were Ghanaian and 56 Nigerian. The presence of thyroid-associated ophthalmopathy (TAO) made cure less likely (χ2 P = 0.006, odds ratio = 0.118; 95% confidence interval, 0.027-0.518). Other factors assessed proved to be insignificant. Our findings suggest that hyperthyroid patients with TAO will benefit from a higher RAI dose than their counterparts without TAO.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1833    
    Printed33    
    Emailed0    
    PDF Downloaded158    
    Comments [Add]    

Recommend this journal